

Mina Tadrous

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8096396/publications.pdf>

Version: 2024-02-01

158
papers

3,345
citations

236925

25
h-index

206112

48
g-index

173
all docs

173
docs citations

173
times ranked

4662
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada. <i>Pain</i> , 2022, 163, e129-e136.	4.2	3
2	Audit and feedback in community pharmacy: An untapped strategy of quality improvement. <i>Canadian Pharmacists Journal</i> , 2022, 155, 79-81.	0.8	0
3	Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 257-259.	1.9	6
4	The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. <i>Depression and Anxiety</i> , 2022, 39, 156-162.	4.1	14
5	Understanding Engagement and the Potential Impact of an Electronic Drug Repository: Multi-Methods Study. <i>JMIR Formative Research</i> , 2022, 6, e27158.	1.4	1
6	Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1491-1499.	3.0	25
7	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	0
8	Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer: A population-based retrospective cohort study in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2022, 40, 529-529.	1.6	1
9	Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis. <i>American Heart Journal Plus</i> , 2022, 13, 100096.	0.6	5
10	Comparisons of Insulin Spending and Price Between Canada and the United States. <i>Mayo Clinic Proceedings</i> , 2022, 97, 573-578.	3.0	2
11	Interprovincial variation in antibiotic use in Canada, 2019: a retrospective cross-sectional study. <i>CMAJ Open</i> , 2022, 10, E262-E268.	2.4	2
12	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group. <i>Current Oncology</i> , 2022, 29, 2046-2063.	2.2	2
13	Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 846.	7.4	43
14	Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study. <i>Addiction</i> , 2022, 117, 1972-1981.	3.3	9
15	Trends in Canadian prescription drug purchasing: 2001-2020. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, 20.	2.4	3
16	Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors. <i>Canadian Journal of Hospital Pharmacy</i> , 2022, 75, 104-107.	0.1	1
17	National trends in prescription drug expenditures and projections for 2022. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1158-1172.	1.0	22
18	Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis. <i>International Journal of Drug Policy</i> , 2022, 103, 103644.	3.3	17

#	ARTICLE	IF	CITATIONS
19	Hospital pharmacist discharge care is independently associated with reduced risk of readmissions for patients with chronic obstructive pulmonary disease: A propensity-matched cohort study. <i>Canadian Pharmacists Journal</i> , 2022, 155, 101-106.	0.8	1
20	Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study. <i>Canada Communicable Disease Report</i> , 2022, 48, 170-178.	1.3	1
21	Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. <i>Cmaj</i> , 2022, 194, E556-E560.	2.0	5
22	Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109459.	3.2	6
23	International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 779-787.	1.9	5
24	Virtual care use during the COVID-19 pandemic and its impact on healthcare utilization in patients with chronic disease: A population-based repeated cross-sectional study. <i>PLoS ONE</i> , 2022, 17, e0267218.	2.5	30
25	Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109473.	3.2	3
26	Agreement and Correlation Between Different Topical Corticosteroid Potency Classification Systems. <i>JAMA Dermatology</i> , 2022, 158, 796.	4.1	6
27	Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 279-284.	5.8	8
28	Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis. <i>Addiction</i> , 2021, 116, 1514-1520.	3.3	11
29	Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 379-389.	1.9	12
30	The missed opportunity for real-world evidence to shape our understanding of medical cannabis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 732-734.	2.4	3
31	Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 739-745.	4.7	16
32	Atopic dermatitis and bone health: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 615-628.	2.4	12
33	"Fitting in the pharmacist™" – a qualitative analysis of the perceived relationship between community pharmacists and older adults with complex care needs. <i>International Journal of Pharmacy Practice</i> , 2021, 29, 428-434.	0.6	1
34	Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada. <i>Canadian Liver Journal</i> , 2021, 4, 426-429.	0.9	4
35	A qualitative study of a publicly funded pharmacy-dispensed naloxone program. <i>International Journal of Drug Policy</i> , 2021, 92, 103146.	3.3	16
36	Choppy waters: The importance of accounting for shifting drug utilization during the COVID-19 pandemic in future observational drug-related studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 649-651.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Safety of Systemic Medications Among Older Adults With Psoriasis and Atopic Dermatitis: A Systematic Review of Observational Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 397-408.	1.2	2
38	Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. <i>Canadian Liver Journal</i> , 2021, 4, 51-58.	0.9	5
39	Sum of the parts: Ensuring a resilient global drug supply chain. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 598-599.	1.8	5
40	Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 581-583.	2.2	2
41	Control yourself: ISPE endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 671-684.	1.9	36
42	Effects of a single-entry intake system on access to outpatient visits to specialist physicians and allied health professionals: a systematic review. <i>CMAJ Open</i> , 2021, 9, E413-E423.	2.4	8
43	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 444-452.	0.9	2
44	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. <i>American Journal of Gastroenterology</i> , 2021, 116, 1738-1740.	0.4	4
45	Rural Telemedicine Use Before and During the COVID-19 Pandemic: Repeated Cross-sectional Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e26960.	4.3	102
46	National trends in prescription drug expenditures and projections for 2021. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1294-1308.	1.0	32
47	Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization Vigibase. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e1017-e1021.	1.6	9
48	Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 549.	4.1	40
49	Dental Opioid Prescription Characteristics and the Risk of New, Persistent Use. <i>American Journal of Preventive Medicine</i> , 2021, 60, 831-839.	3.0	9
50	Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. <i>Viruses</i> , 2021, 13, 1314.	3.3	11
51	Measuring the impacts of the Using Antibiotics Wisely campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2472-2478.	3.0	7
52	Old dog with new tricks: An introduction to real-world evidence for pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2277-2280.	1.0	5
53	Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic. <i>Chest</i> , 2021, 160, 2123-2134.	0.8	5
54	Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada. <i>JAMA Network Open</i> , 2021, 4, e2118441.	5.9	67

#	ARTICLE	IF	CITATIONS
55	Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. <i>BMJ</i> , The, 2021, 374, n1943.	6.0	245
56	Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects. <i>Frontiers in Pharmacology</i> , 2021, 12, 709349.	3.5	1
57	Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments. <i>Vaccine</i> , 2021, 39, 5265-5270.	3.8	4
58	Opioid Prescribing in United States Health Systems, 2015 to 2019. <i>Value in Health</i> , 2021, 24, 1279-1284.	0.3	4
59	Using Administrative Data to Explore Potentially Aberrant Provision of Virtual Care During COVID-19: Retrospective Cohort Study of Ontario Provincial Data. <i>Journal of Medical Internet Research</i> , 2021, 23, e29396.	4.3	2
60	Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. <i>CMAJ Open</i> , 2021, 9, E107-E114.	2.4	152
61	Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group. <i>Current Oncology</i> , 2021, 28, 4174-4183.	2.2	8
62	Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. <i>JAMA Network Open</i> , 2021, 4, e2130795.	5.9	17
63	Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1504.	7.4	38
64	Comparison of claims from high-cost drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. <i>CMAJ Open</i> , 2021, 9, E1048-E1054.	2.4	0
65	Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. <i>Current Oncology</i> , 2021, 28, 4645-4654.	2.2	10
66	Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: a cross-sectional time-series analysis. <i>BMJ Global Health</i> , 2021, 6, e006874.	4.7	10
67	The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis. <i>CMAJ Open</i> , 2021, 9, E1181-E1186.	2.4	1
68	Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. <i>CMAJ Open</i> , 2021, 9, E1055-E1062.	2.4	5
69	Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study. <i>CMAJ Open</i> , 2021, 9, E1128-E1133.	2.4	10
70	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 444-452.	0.9	1
71	Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 12-19.	0.5	5
72	Assessing the impact of an opioid prescribing guideline for dentists in Ontario, Canada. <i>Journal of the American Dental Association</i> , 2020, 151, 43-50.	1.5	6

#	ARTICLE	IF	CITATIONS
73	Topical corticosteroids and type 2 diabetes mellitus: a critical appraisal. <i>British Journal of Dermatology</i> , 2020, 183, 37-38.	1.5	0
74	Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. <i>Value in Health</i> , 2020, 23, 1137-1141.	0.3	14
75	Topical Calcineurin Inhibitors and Skin Cancer—Another Piece of the Puzzle. <i>JAMA Dermatology</i> , 2020, 156, 1053.	4.1	3
76	National trends in prescription drug expenditures and projections for 2020. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1213-1230.	1.0	34
77	Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 1240.	4.1	24
78	Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108238.	3.2	9
79	Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 864-872.	1.9	22
80	Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes. <i>JAMA Network Open</i> , 2020, 3, e205724.	5.9	12
81	Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. <i>BMJ Open</i> , 2020, 10, e032884.	1.9	32
82	Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle. <i>Healthcare Policy</i> , 2020, 15, 41-47.	0.6	4
83	Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis. <i>Europace</i> , 2020, 22, 854-869.	1.7	9
84	Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis. <i>CMAJ Open</i> , 2020, 8, E297-E303.	2.4	3
85	Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department: A Systematic Review and Network Meta-analysis. <i>Annals of Emergency Medicine</i> , 2020, 76, 14-30.	0.6	12
86	Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. <i>Canadian Journal of Diabetes</i> , 2019, 43, 179-185.e1.	0.8	11
87	Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2019, 8, 207.	5.3	25
88	Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older—A Population-Based Cohort Study. <i>JAMA Internal Medicine</i> , 2019, 179, 1436.	5.1	6
89	The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study. <i>PLoS ONE</i> , 2019, 14, e0223589.	2.5	27
90	Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. <i>JAMA Network Open</i> , 2019, 2, e1913304.	5.9	19

#	ARTICLE	IF	CITATIONS
91	Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. <i>CMAJ Open</i> , 2019, 7, E582-E589.	2.4	14
92	“Like being put on an ice floe and shoved away” A qualitative study of the impacts of opioid-related policy changes on people who take opioids. <i>International Journal of Drug Policy</i> , 2019, 66, 15-22.	3.3	63
93	National trends in prescription drug expenditures and projections for 2019. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1105-1121.	1.0	29
94	Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer’s Dementia. <i>PLoS ONE</i> , 2019, 14, e0215225.	2.5	2
95	Impact of delisting high-strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 726-733.	1.9	14
96	Evaluation of the fentanyl patch-for-patch program in Ontario, Canada. <i>International Journal of Drug Policy</i> , 2019, 66, 82-86.	3.3	8
97	Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. <i>BMJ Open</i> , 2019, 9, e028125.	1.9	10
98	WHAT’S OLD IS NEW: USING ARTIFICIAL INTELLIGENCE TO ACCELERATE DISCOVERY OF NEW TREATMENTS. <i>Innovation in Aging</i> , 2019, 3, S16-S17.	0.1	0
99	Further Evidence to Monitor Long-term Proton Pump Inhibitor Use. <i>JAMA Network Open</i> , 2019, 2, e1916184.	5.9	11
100	PD31-12 MIRABEGRON AND THE RISK OF ARRHYTHMIAS: A POPULATION-BASED COHORT STUDY. <i>Journal of Urology</i> , 2019, 201, .	0.4	0
101	Quality of primary care among individuals receiving treatment for opioid use disorder. <i>Canadian Family Physician</i> , 2019, 65, 343-351.	0.4	18
102	Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. <i>Neurourology and Urodynamics</i> , 2018, 37, 1693-1700.	1.5	3
103	Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. <i>European Urology Supplements</i> , 2018, 17, e1539.	0.1	0
104	Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program. <i>CMAJ Open</i> , 2018, 6, E132-E138.	2.4	4
105	Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 361-369.	1.9	56
106	Measuring the Burden of Opioid-related Mortality in Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2018, 12, 418-419.	2.6	43
107	Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. <i>Canadian Geriatrics Journal</i> , 2018, 21, 269-273.	1.2	13
108	Opioids in Ontario: the current state of affairs and a path forward. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 927-929.	3.1	3

#	ARTICLE	IF	CITATIONS
109	Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. <i>BMJ: British Medical Journal</i> , 2018, 362, k3207.	2.3	103
110	Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study. <i>Pain</i> , 2018, 159, 1562-1568.	4.2	60
111	Network meta-analysis: an introduction for pharmacists. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 942-947.	2.1	5
112	The Burden of Opioid-Related Mortality in the United States. <i>JAMA Network Open</i> , 2018, 1, e180217.	5.9	484
113	History and publication trends in the diffusion and early uptake of indirect comparison meta-analytic methods to study drugs: animated coauthorship networks over time. <i>BMJ Open</i> , 2018, 8, e019110.	1.9	8
114	A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 160.	1.9	4
115	Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 464-468.	0.9	2
116	Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study. <i>Drug and Alcohol Dependence</i> , 2018, 191, 86-90.	3.2	24
117	Opioid prescribing and adverse events in opioid-naive patients treated by emergency physicians versus family physicians: a population-based cohort study. <i>CMAJ Open</i> , 2018, 6, E110-E117.	2.4	14
118	Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: A population-based study. <i>Respiratory Medicine</i> , 2018, 143, 1-7.	2.9	5
119	Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002584.	8.4	82
120	Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 59-65.e2.	1.0	18
121	Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2018, 38, 256-262.	1.1	10
122	Linking the Narcotics Monitoring System Database to Quantify the Contribution of Prescribed and Non-Prescribed Opioids to Opioid Overdoses in Ontario, Canada. <i>International Journal of Population Data Science</i> , 2018, 3, .	0.1	2
123	Characteristics of Opioid-Related Deaths in Ontario, Canada: Leveraging the Drug and Drug/Alcohol Related Death (DDARD) Database. <i>International Journal of Population Data Science</i> , 2018, 3, .	0.1	1
124	Diffusion of Innovations model helps interpret the comparative uptake of two methodological innovations: co-authorship network analysis and recommendations for the integration of novel methods in practice. <i>Journal of Clinical Epidemiology</i> , 2017, 84, 150-160.	5.0	16
125	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <i>Cmaj</i> , 2017, 189, E4-E10.	2.0	41
126	Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis. <i>Pain Medicine</i> , 2017, 18, 1019-1026.	1.9	28

#	ARTICLE	IF	CITATIONS
127	Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. <i>Drug and Alcohol Dependence</i> , 2017, 177, 315-321.	3.2	18
128	Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes. <i>JAMA Internal Medicine</i> , 2017, 177, 61.	5.1	15
129	The appropriateness and persistence of testosterone replacement therapy in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 119-126.	1.9	7
130	Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study. <i>Canadian Urological Association Journal</i> , 2017, 12, E142-5.	0.6	5
131	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. <i>Healthcare Policy</i> , 2017, 13, 68-78.	0.6	2
132	Off-label use of inhaled tobramycin in Ontario, Canada. <i>Thorax</i> , 2016, 71, 862-864.	5.6	1
133	Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 803-807.	1.4	0
134	Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. <i>Drugs - Real World Outcomes</i> , 2016, 3, 175-182.	1.6	12
135	Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs. <i>Canadian Journal of Diabetes</i> , 2016, 40, 431-435.	0.8	11
136	Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 758-765.	1.9	20
137	Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. <i>Osteoporosis International</i> , 2016, 27, 1989-1998.	3.1	45
138	Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. <i>Osteoporosis International</i> , 2016, 27, 1709-1718.	3.1	106
139	Varenicline and Risk of Self-Harm: A Nested Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0163681.	2.5	1
140	Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. <i>Implementation Science</i> , 2015, 11, 45.	6.9	18
141	Performance of the disease risk score in a cohort study with policy-induced selection bias. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 607-614.	1.4	0
142	Initial uptake of the Ontario Pharmacy Smoking Cessation Program. <i>Canadian Pharmacists Journal</i> , 2015, 148, 29-40.	0.8	16
143	Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. <i>Osteoporosis International</i> , 2015, 26, 1525-1533.	3.1	13
144	Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study. <i>CMAJ Open</i> , 2015, 3, E91-E96.	2.4	6

#	ARTICLE	IF	CITATIONS
145	Proceed with caution. Canadian Pharmacists Journal, 2014, 147, 273-274.	0.8	0
146	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporosis International, 2014, 25, 1225-1235.	3.1	44
147	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysisâ€”reply to Pazianas and Abrahamsen. Osteoporosis International, 2014, 25, 2671-2672.	3.1	10
148	Variation in the days supply field for osteoporosis medications in Ontario. Archives of Osteoporosis, 2013, 8, 128.	2.4	11
149	Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open, 2013, 1, E97-E105.	2.4	8
150	Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiology and Drug Safety, 2013, 22, 122-129.	1.9	44
151	Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 699-709.	1.4	8
152	Does depression lead to influenza? â€” A systematic literature analysis. Journal of Affective Disorders, 2012, 138, 41-45.	4.1	4
153	Establishing a Complete Drug Information Triad: Academic, Industry, and Hospital Training. Drug Information Journal, 2011, 45, 641-644.	0.5	1
154	Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials. Digestive Diseases and Sciences, 2011, 56, 7-18.	2.3	58
155	Thimerosal-containing vaccines and autism: a review of recent epidemiologic studies. Journal of Pediatric Pharmacology and Therapeutics, 2010, 15, 173-81.	0.5	11
156	First renin inhibitor, aliskiren, for the treatment of hypertension. International Journal of Clinical Pharmacy, 2008, 30, 741-749.	1.4	5
157	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines Against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario, Canada. SSRN Electronic Journal, 0, , .	0.4	16
158	Comparison of admission rates to a non-traditional Doctor of Pharmacy programme using internet-based multiple-mini interviews versus on-site. Pharmacy Education, 0, , 282-286.	0.6	1